Extended Data Fig. 10: Risk of clinical progression based on either high LDH or CAR TReg fraction alone.
From: Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy

a, Pearson correlation between pre-LD LDH levels and percentage of CD57–Helios+ (TReg-like) cells among CD4+ CAR T cells in blood on day 7 post-infusion colored by response at 6 months (n = 53). P value is from the correlation test. b, Percentage of CAR TReg cells separated by normal or high pre-LD LDH levels (n = 53). c, Percentage of CAR TReg cells in patients with CR or PD at 6 months with normal pre-LD LDH (left, n = 25) or high pre-LD LDH (right, n = 26). Boxplots in (b,c) show quartiles with a band at median, whiskers indicating 1.5x IQR, and all observations overlaid as dots. P values are from two-sided Mann-Whitney U test. d, Logistic regression models for predicting response at 6 months based on either percent of CAR TReg cells (top, n = 28), or whether pre-LD LDH levels were above normal (bottom, n = 29). Models were fit using all available data from the discovery cohort, with parameters shown below the formula. e, Performance of each model from (d) on discovery (top, n = 28; bottom, n = 29) and validation (top, n = 23; bottom, n = 33) cohorts. All available data not in the discovery cohort were used to test each model (Supplementary Table 5). AUROC, area under the receiver operating characteristic. f,g, Kaplan-Meier analysis of TTP (f) and OS (g) stratified by high vs. low risk using the models from (d) on cohorts from (e).